Larynx Preservation: Advantages and Limitations by Zoran Rakušić & Vesna Bišof
Coll. Antropol. 36 (2012) Suppl. 2: 231–233
Review article
Larynx Preservation: Advantages and Limitations
Zoran Raku{i}¹ and Vesna Bi{of²
1 University of Zagreb, Zagreb University Hospital Center, Department of Oncology, Zagreb, Croatia
2 University of Zagreb, Zagreb University Hospital Center, Department of Oncology, Zagreb, Croatia
A B S T R A C T
For a long time standard treatment approach for resectable squamous cell carcinoma of larynx was surgery with or
without subsequent radiotherapy. Surgery, particulary total laryngectomy, has been associated with serious impairment
of quallity of life. Between nonsurgical approaches, concurrent cisplatin based chemoradiotherapy has become a very
promising treatment modality for larynx preservation. However, concurrent chemotherapy has been associated with seri-
ous toxicity. The most recent treatment approach in larynx preservation is related to taxan based induction chemother-
apy.
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Introduction
Until 1980s the method of choice for treatment of ad-
vanced laryngeal cancer was total laryngectomy with or
without postoperative radiotherapy. This modality fused
reasonable treatment results but insufficient quality of
life for operated patients. Permanent tracheotomy and
loss of speech were main obstacles for generally accep-
tance of this treatment approach between patients and
physicians.
Based on results of concurrent and induction chemo-
therapy randomised trials performed in 1990s, larynx
preservation has become a desirable treatment approach
for advanced laryngeal cancer.
Combined-modality Studies in Larynx
Preservation
The first randomized study demonstrated advantage
in larynx preservation was published in 1991 by Veterans
Department1. It comprised 332 patients with advanced
stage laryngeal carcinoma (stage III and IV) randomized
to the induction chemotherapy cisplatin plus 5- fluorou-
racil (PF) followed by surgery versus same induction che-
motherapy followed by definitive radiotherapy at dose
66–76 Gy. There was a significant benefit represented by
larynx preservation in 2/3 of patients treated with 3 cy-
cles of induction chemotherapy and definitive radiother-
apy. The overall survival did not differ between the
treatment groups.
Adelstein et al.2 compared definitive radiotherapy and
concurrent PF chemoradiotherapy in the larynx preser-
vation setting. At 5 years there was a benefit in rate of
larynx preservation in the group with concurrent che-
moradiotherapy (26% vs 16%, p=0.03), without compro-
mising the overall survival.
The Radiation Therapy Oncology Group (RTOG) ran-
domized trial 91–113 demonstrated significantly higher
proportion of larynx preservation in concurrent cispatin
based chemoradiotherapy group than in the sequential
chemotherapy PF and radiotherapy group (at 2 years
88% : 75% respectively; p=0.005). This advantage of con-
current chemoradiotherapy in larynx preservation was
accompanied with significant increase in acute toxicity,
especially mucositis grade 3 and 4 (43% : 24% respec-
tively). At 5 years there was no significant difference in
larynx preservation in both treatment arms. The third
arm of the trial, radiotherapy alone, was significantly in-
ferior in terms of larynx preservation rate in comparison
with both concurrent and induction chemotherapy arm.
The Groupe Oncologie Radiotherapie Tete et Cou
(GORTEC) 2000–01 trial4 showed that larynx preserva-
tion rate achieved with PF induction chemotherapy fol-
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lowed by radiotherapy may be improved by adding the
docetaxel to the standard induction chemotherapy proto-
col PF – TPF (taxotere, cisplatin, 5 fluorouracil). The
subgroup analysis revealed that addition of docetaxel to
PF induction chemotherapy, prior to the concurrent che-
moradiotherapy led to a significantly higher laryngec-
tomy free survival (LFS) rate than with PF (p=0.03),
without compromising survival.
The authors of Phase II trial TREMPLIN5 reported
about the contribution of epidermal growth factor recep-
tor (EGFR) inhibitor, cetuximab, to larynx preservation
in patients treated with TPF induction chemotherapy.
This trial compared induction TPF chemotherapy fol-
lowed by concurrent chemoradiotherapy with induction
TPF chemotherapy followed by concurrent cetuximab
plus radiotherapy. At 3 months there was no difference in
the larynx preservation rate between treatment arms. It
was pointed out that cetuximab plus radiotherapy was
better tolerated than concurrent chemoradiotherapy.
Only 43% of patients were capable to receive full chemo-
radiotherapy regimen, compared with 71% of patients in
cetuximab plus radiotherapytreatment arm.
Disscusion
In spite of numerous trials performed during last two
decades there are still lot of controversies about indica-
tions and treatment modalities in larynx preservation
concept. Larynx preservation consensus panel, which
members were leading experts in head and neck oncology
all round the world, discussed the key issues and gave
recommendations for larynx preservation trials6. Accord-
ing them, T4 patients are not the best candidates for lar-
ynx preservation approach due to the reduced tumor re-
sponse to chemotherapy and more frequent salvage
laryngectomy in these patients. It is particularly related
to T4 tumors which extend through the cartilage into the
neck soft tissue. Such patients are not suitable for con-
servative approach but rather for the initial surgery. Tu-
mors exhibiting minimal cartilage invasion remain clas-
sified as T3 and are eligible for larynx preservation
approach. Wide spectrum of T2 tumors are candidates
both for conservative as well as for surgical treatment.
Generally, patients with T2 disease eligible for partial
laryngectomy should be excluded from larynx preserva-
tion trials. Contrary, patients with endophytic T2 tumors
or with clinical lymphadenopathy might be associated
with lymph node involvement and extracapsular exten-
sion. These patients are at high risk for regional or/and
distal relapse and should be treated with adjuvant che-
moradiotherapy. Such trimodality therapy, in terms of
functional results, is worse than initial larynx preserva-
tion approach.
Regarding the N stage of laryngeal cancer, panelists
emphasized the increased risk of distant metastasis in
patients with N2 and N3 disease. There is also increased
risk for extracapsular spread in these patients. Gen-
erally, trials which used induction chemotherapy as ini-
tial treatment, reported reduced risk for distal relapse
comparing with non-chemotherapy treatment approa-
ches.
The special attention was paid to the evaluation of
baseline laryngeal dysfunction. The indicators for base-
line laryngeal dysfunction include a tracheotomy, gastric
tube, and recent history of pneumonia. Patients with tra-
cheotomy were included in RTOG 91–11 trial3, but were
excluded from EORTC 246547. There is still no consen-
sus about this issue. The history of recent pneumonia re-
quiring hospitalization represents serious toxicity and
may confuse data in toxic evaluation.
The patients stratification in trials based on perfor-
mance status is more acceptable option than stratifica-
tion based on age alone8. In subset analysis of the Meta-
-analysis of chemotherapy in head and neck cancer
(MACH-NC)9, patients older than 70 years of age had no
benefit of chemotherapy. Although the reasons for ex-
cluding elderly from chemotherapy trials are not com-
pletely transparent, panelist didn’t recommend induc-
tion or concurrent chemotherapy in these settings.
What has been achieved in larynx preservation ap-
proach and what we can expect in the future? The sur-
vival of patients with laryngeal cancer is, unfortunately,
decreasing. Some experts have found possible explana-
tion of decreasing survival rate of laryngeal cancer pa-
tients, in overused induction chemotherapy approach
with final endpoint of spearing larynx. For sure, chemo-
therapy alone is not curative, even in the best circum-
stances10. Concurrent chemoradiotherapy allows higher
dose intensity which has been shown to improve loco-
regional control. Furthermore, long term toxicity profile
of concurrent chemoradiotherapy is considerable, espe-
cially mucositis. There are, generally, two frequently
mentioned factors in favor of sequential therapy. The
first one is that the response to the induction chemother-
apy allows better selection of postinduction treatment
approach, providing less acute and late toxicity. The sec-
ond, the shrinkage of pretreatment tumor volume after
use of induction chemotherapy improves delivery and
treatment results of Intensity Modulated Radiation The-
rapy (IMRT). The last alleged advantage is doubtful. In
fact, tumor shrinkage after induction chemotherapy is
not referential for radiotherapy target volume. Shrink-
age of the preinduction tumor volume for radiotherapy
planning can jeopardize the treatment results. The in-
duction chemotherapy delays definitive radiotherapy
treatment which is substantial in the larynx preserva-
tion concept. Even more, induction chemotherapy has a
serious toxicity including toxic death rate in range of
1–5%11. Postinduction therapy with concurrent chemora-
diotherapy is more toxic and less effective that treatment
with concurrent chemotherapy alone. Of particular con-
cern is whether any toxicity associated with induction
chemotherapy will compromise the optimal administra-
tion of postinduction chemotherapy and radiotherapy. It
is particularly addressed to docetaxel related myelotoxi-
city12. The application of target agents like monoclonal
antibodies and tyrosine kinase inhibitors in the postin-
duction setting is still under investigation. For the final
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judgment of successful laryngeal outcome, except larynx
preservation rate, the laryngectomy-free survival (LFS)
is of outstanding importance. The larynx preservation
approach represents not only anatomical, but also func-
tional larynx spearing procedure13,14.
Conclusion
Since early 1990s the larynx preservation approach is
challenging issue in the treatment of advanced laryngeal
cancer. Nowadays, we know that the addition of chemo-
therapy to radiotherapy enables larynx preservation in
patients who are candidates for total laryngectomy. The
concurrent chemoradiotherapy is still preferable option,
comparing with induction chemotherapy, in terms of sur-
vival. Due to early and late toxicity of concurrent chemo-
therapy, treatment with induction chemotherapy is ac-
ceptable possibility in larynx preservation approach. The
induction chemotherapy with triplet TPF demonstrated
superior treatment results comparing with PF. Thus, the
TPF is considered as standard induction chemotherapy
approach worldwide. The most effective postinduction
treatment modality is still issue which should be recog-
nized. The role of target agents in postinduction setting
has to be defined. Future trials, based on careful pre-
treatment patients’ selection, have to find answers on
these questions. Radiotherapy still remains crucial part
of larynx preservation approach.
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O^UVANJE LARINKSA: PREDNOSTI I OGRANI^ENJA
S A @ E T A K
Dugo vremena standardno lije~enje operabilnog planocelularnog karcinoma larinksa bila je operacija uz ili bez post-
operativne radioterapije. Operacija, osobito totalna laringektomija, povezana je s ozbiljnim naru{avanjem kvalitete
`ivota. Izme|u nekirur{kih pristupa, konkomitantna kemoterapija sa cisplatinom postala je obe}avaju}a metoda lije-
~enja u o~uvanju larinksa, ali je povezana sa zna~ajnim nuspojavama. Najsuvremenije lije~enje uznapredovalih stadija
tumora, uz o~uvanje larinksa, povezano je s indukcijskom kemoterapijom taksanima.
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